Fundamentals of Multiple Sclerosis Care – Part 1: Diagnosing the Disease and Managing Specific Populations

Release date: February 1, 2022
Valid through: January 31, 2024

Estimated Time to Complete Activity: 2 hours, 45 minutes

Target Audience

This activity has been designed to meet the educational needs of physicians, advanced practice clinicians, nursing professionals, pharmacists, psychologists, social workers, rehabilitation specialists, dietitians, researchers, advocates, and other members of the healthcare team involved in the management of patients with MS, conduct research in MS or who have a special interest in MS.


Fundamentals of Multiple Sclerosis Care offers a multidisciplinary approach in the diagnosis and management of multiple sclerosis (MS). The history of MS will offer participants an insight into the disease and the changes that have led to improved approaches to management. A comprehensive overview of MS will be presented to include epidemiology, immunology, pathophysiology, natural history, and clinical course. Presentations will include what is involved in making the diagnosis of MS, disease mimics and use of paraclinical tools. Specific populations, including Pediatric MS, will be wrap up Part 1.

Topics and Faculty

  • Introduction and Moderator – Patricia Pagnotta, ANP-C, MSCN
  • History of Multiple Sclerosis – Randall Schapiro, MD, FAAN
  • The Natural History of MS (Epidemiology, Immunology, Pathophysiology) – Bruce Cohen, MD
  • Making the Diagnosis: Disease Mimics, Use of Paraclinical Tools – Derrick Robertson, MD
  • Pediatric MS: Management and Transition to Adult Care – Jennifer Boyd, RN, MHSc, MSCN

Learning Objectives

Upon completing this activity, participants should be better able to:

  • Examine the various models of care in MS and the roles and responsibilities of care team members in order to adapt the most appropriate model for team-based care in a given practice setting.
  • Integrate the complex processes that support the provision of team-based, comprehensive care in MS into effective practices and centers providing evidence-based MS care.
  • Integrate information about the mechanisms underlying MS relapses, progression, and gray and white matter pathology as the basis for monitoring and treating the disease.
  • Summarize methods to monitor treatment outcomes including patient self-report, automated self-assessment, new clinician reported outcomes, imaging, and biomarkers in order to optimize their utilization in clinical practice and research.

Accreditation and Credit Designation

In support of improving patient care, The Consortium of Multiple Sclerosis Centers is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 2.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Consortium of Multiple Sclerosis Centers designates this enduring material for 2.75 nursing continuing professional development (NCPD) credits.

This knowledge-based activity (UAN JA4008165-0000-22-007-H01-P) qualifies for 2.75 contact hour (.275 CEUs) of continuing pharmacy education credit.

Physician Assistants (PAs)
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.75 AAPA Category 1 CME credits. Approval is valid until January 31, 2024. PAs should only claim credit commensurate with the extent of their participation.

Psychologists (APA)
The activity is awarded 2.75 CE credits.

Social Workers (Through ASWB’s ACE Program) (SW)
As a Jointly Accredited Organization, the CMSC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The CMSC maintains responsibility for this course. Social workers completing this course receive 2.75 continuing education credits.

Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.

Disclosure of Financial Relationships

In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC requires that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seeks to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

Faculty Disclosures

The program faculty reported the following relevant financial relationships with ineligible companies:

  • Jennifer Boyd, RN, MHSc, MSCN has disclosed no relevant financial relationships with ineligible companies.
  • Bruce Cohen, MD has disclosed the following relevant financial relationships with ineligible companies: Consultant: Bristol Myers Squibb; Research Support: Genentech; funding for multicenter clinical trial: MedDay Pharmaceuticals.
  • Patricia Pagnotta, ANP-C, MSCN has disclosed the following relevant financial relationships with ineligible companies: Consultant, Speaker: AbbVie, Biogen, Genentech, Mallinckrodt Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals.
  • Derrick Robertson, MD has disclosed the following relevant financial relationships with ineligible companies: Speaker, Consultant, Advisor, Research: Acorda Therapeutics, Inc., Actelion Pharmaceuticals, Alexion Pharmaceuticals, Biogen, Bristol Myers Squibb, EMD Serono, Inc., Genentech, Greenwich Biosciences, Janssen Pharmaceuticals, Mallinckrodt Pharmaceuticals, MedDay Pharmaceuticals, Novartis Pharmaceuticals Co.
  • Randall Schapiro, MD, FAAN has disclosed no relevant financial relationships with ineligible companies.

All of the relevant financial relationships listed for these individuals have been mitigated.

Staff Disclosures

The planners, reviewers, editors, staff, or other members of CMSC who are in a position to control content have disclosed no relevant financial relationships.

Technical Requirements

This activity is best viewed using the latest version of Chrome, Edge, or Firefox.

Method of Participation

To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) view the educational activity, and (3) complete the activity evaluation.

How to Claim Credit

  • To complete the evaluation and claim credit, go to
  • Create a new account or log in with your user name and password*.
  • Select the Enduring Materials tab, then select this activity from the listing and follow the instructions to complete the activity and receive your credit.

*If you forgot your username or password, click on Forgot password. You will receive an email with a link to change your password.

There are no fees to participate in this activity.

Disclosure of Unlabeled Use

CMSC requires faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

CMSC has not received commercial support for this activity.


CMSC presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC assumes no liability for the information herein.

Privacy Policy

To view the CMSC Privacy Policy, visit our website at

Contact Information

If you have any questions about this activity, please contact the CMSC at [email protected].